Zifeng Wang
Hokkaido University
5 Papers
Zifeng Wang is an academic researcher from Hokkaido University. The author has contributed to research in topics: Inflammation & Stroke. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
FTY720 Protects Against Ischemia–Reperfusion Injury by Preventing the Redistribution of Tight Junction Proteins and Decreases Inflammation in the Subacute Phase in an Experimental Stroke Model
Zifeng Wang,Kei Higashikawa,Hironobu Yasui,Yuji Kuge,Yusuke Ohno,Akio Kihara,Yenari A. Midori,Kiyohiro Houkin,Masahito Kawabori +8 more
TL;DR: It is suggested that FTY720 can ameliorate I/R injury by protecting the BBB and regulating neuroinflammation by blocking the worsening of inflammation in later stages.
[18F]DPA-714 PET imaging shows immunomodulatory effect of intravenous administration of bone marrow stromal cells after transient focal ischemia
Chengbo Tan,Chengbo Tan,Songji Zhao,Songji Zhao,Kei Higashikawa,Zifeng Wang,Masahito Kawabori,Takeo Abumiya,Naoki Nakayama,Ken Kazumata,Naoyuki Ukon,Naoyuki Ukon,Hironobu Yasui,Nagara Tamaki,Yuji Kuge,Hideo Shichinohe,Kiyohiro Houkin +16 more
TL;DR: It is suggested that BMSC therapy could be effective in ischemic stroke due to modulation of systemic inflammatory responses and the [18F]DPA-714 PET/CT system can accurately demonstrate brain inflammation and evaluate the B MSC therapeutic effect in an imaging context.
Responses of Immune Organs after Cerebral Ischemic Stroke.
Chengbo Tan,Chengbo Tan,Chengbo Tan,Zifeng Wang,Miao Zheng,Songji Zhao,Hideo Shichinohe,Kiyohiro Houkin +7 more
TL;DR: Stroke is a systemic disease, which not only affects the brain, but also induces responses of immune organs, and on the basis of these results, a systemic treatment might be a good strategy for clinical stroke care.
3
FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment.
TL;DR: Its efficacy against cerebral stroke is becoming clear, not only in animal models, but also in ischemic stroke patients through clinical trials and the data obtained from laboratory findings and preliminary clinical trials using FTY720 for stroke treatment are reviewed.
Feasibility and Efficiency of Human Bone Marrow Stromal Cell Culture with Allogeneic Platelet Lysate-Supplementation for Cell Therapy against Stroke.
Chengbo Tan,Hideo Shichinohe,Zifeng Wang,Shuji Hamauchi,Takeo Abumiya,Naoki Nakayama,Ken Kazumata,Tsuneo Ito,Kohsuke Kudo,Shigeru Takamoto,Kiyohiro Houkin +10 more
TL;DR: The hBMSCs cultured with allogeneic PL are suitable for cell therapy against stroke, and no contradiction in cell surface markers and no chromosomal aberrations were found.